UNITED THERAPEUTICS Corp (UTHR) stock
Close on Nov 12, 2026Market cap $25.45BP/E 22.4Yield –
UNITED THERAPEUTICS Corp grew revenue 1.9% to $3.19B over the twelve months to Sep 30, 2026. Operating income fell 11.5% to $1.32B, moving the operating margin from 47.7% to 41.4%. Free cash flow was $867.20M, down 22.7% from a year earlier. At the latest close the market valued the company at $25.45B, 22.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $25.45B
- P/E ratio
- 22.4
- Price to sales
- 7.98
- Price to book
- 4.05
- Dividend yield
- –
- Free cash flow yield
- 3.41%
Fundamentals
- Revenue
- $3.19B
- Net income
- $1.23B
- EPS, diluted
- $26.50
- Free cash flow
- $867.20M
- Book value per share
- $138.54
- Diluted shares
- 45M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $595.66
- Open
- $597.50
- Day's range
- $586.56 – $598.38
- Volume
- 338,726
- Average volume (20 days)
- 537,533
- Index membership
- S&P MidCap 400, Russell 1000, Russell 3000
- Beta (5 years)
- 0.55
- 52-week range
- $452.44 – $614.23
- RSI (14 days)
- 59.0
- Volatility (1 year)
- 34.9%
- Relative volume
- 0.53×
- WACC
- 7.6%
On 1 of our idea list: Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | UTHR | S&P 500 | Difference | UTHR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.9% | -2.7% | +10.6 pts | ||
| 3 months | +15.9% | -1.7% | +17.7 pts | ||
| Year to date | +21.8% | +11.9% | +9.9 pts | ||
| 1 year | +28.6% | +12.0% | +16.6 pts | ||
| 3 years | +166.2% | +78.2% | +88.1 pts | +38.6% | +21.2% |
| 5 years | +191.8% | +73.2% | +118.6 pts | +23.9% | +11.6% |
| 10 years | +367.2% | +309.6% | +57.5 pts | +16.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases United Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Update
- Results
- Update
About United Therapeutics
Pharmaceutical Preparations
United Therapeutics Corporation is a biotechnology public benefit corporation that develops and commercializes therapies for rare, life-threatening conditions and develops organ manufacturing technologies. Its primary commercial focus is pulmonary arterial hypertension, which it addresses through treprostinil-based therapies including Tyvaso DPI, nebulized Tyvaso, Remodulin, and Orenitram, alongside the phosphodiesterase type 5 inhibitor Adcirca. Nebulized Tyvaso and Tyvaso DPI are also indicated to treat pulmonary hypertension associated with interstitial lung disease. Additionally, the company markets Unituxin, an oncology biologic targeting high-risk neuroblastoma. The company distributes its products primarily to specialty pharmaceutical distributors within the United States and to pharmaceutical distributors internationally.
Company profile, executives and historyUnited Therapeutics stock: common questions
What is United Therapeutics's stock price?
UTHR closed at $593.31 on Nov 12, 2026, down 0.39% on the day. Over the past 52 weeks it traded between $452.44 and $614.23.
What is United Therapeutics's market cap?
United Therapeutics was worth $25.45B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is UTHR's P/E ratio?
UTHR trades at 22.4 times earnings, based on diluted earnings per share of $26.50 over the twelve months to Sep 30, 2026.
How much revenue does United Therapeutics make?
United Therapeutics reported revenue of $3.19B for the twelve months to Sep 30, 2026, up 1.9% from a year earlier.
Does United Therapeutics pay a dividend?
No. United Therapeutics has not paid a cash dividend over the last twelve months.
When does United Therapeutics report earnings next?
United Therapeutics is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has UTHR stock performed over the past year?
Including dividends, UTHR returned +28.6% over the past year, against +12.0% for the S&P 500.
How many UTHR shares are sold short?
2M shares were sold short at the latest FINRA report, 4.71% of the float, or 3.5 days of average trading volume.
Who are United Therapeutics's competitors?
Companies most similar to United Therapeutics by business, industry and size include BMRN, INSM, LQDA, JAZZ, RARE.
See a number that looks wrong?